title: Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?
abstract: In this study we analyzed whether the polymorphisms 676T>G in the tumor necrosis factor receptor (TNFR) II gene and -308G>A in the TNFalpha promoter gene may influence the response grading to anti-TNFalpha therapy in rheumatoid arthritis. We enrolled and genotyped 105 RA patients treated with etanercept (n = 55), infliximab (n = 40) and adalimumab (n = 10) for 1 year. The clinical response was evaluated according to the ACR criteria every 3 months. Patients with TNFRII 676TG genotype was significantly associated with lower ACR response compared with 676TT genotype, at 3 (OR 3.78 95% CI 1.07-13.31) and 12 months (OR 4.30 95% CI 1.16-15.99) of treatment. No significant association between TNFalpha -308G>A polymorphism and the clinical response was found. TNFRII 676TG genotype is associated with a lower response to anti-TNFalpha therapy, independently from the specific agent used. This polymorphism could become a useful genetic marker for predicting the different response grading to anti-TNFalpha therapy.
authors.affiliation: Department of Morphology and Embryology, Section of Histology, University of Ferrara, Via Fossato di Mortara, 64/B, 44100, Ferrara, Italy. ngrlss@unife.it
authors.forename: Alessia
authors.initials: A
authors.lastname: Ongaro
authors.forename: Monica
authors.initials: M
authors.lastname: De Mattei
authors.forename: Agnese
authors.initials: A
authors.lastname: Pellati
authors.forename: Angelo
authors.initials: A
authors.lastname: Caruso
authors.forename: Stefano
authors.initials: S
authors.lastname: Ferretti
authors.forename: Federica Francesca
authors.initials: FF
authors.lastname: Masieri
authors.forename: Maria
authors.initials: M
authors.lastname: Fotinidi
authors.forename: Ilaria
authors.initials: I
authors.lastname: Farina
authors.forename: Francesco
authors.initials: F
authors.lastname: Trotta
authors.forename: Melissa
authors.initials: M
authors.lastname: Padovan
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011446:Prospective Studies; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D007155:Immunologic Factors; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha